Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime

BACKGROUND: A new estrogen-free contraceptive has been approved by both the FDA and more than 15 European authorities. It is composed of drospirenone (DRSP) at a dosage of 4 mg in a regimen 24/4. The molecule is known to have anti-gonadotropic, anti-mineralocorticoid, anti-estrogenic, and antiandrog...

Descripción completa

Detalles Bibliográficos
Autores principales: Palacios, Santiago, Colli, Enrico, Regidor, Pedro-Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530969/
https://www.ncbi.nlm.nih.gov/pubmed/33008401
http://dx.doi.org/10.1186/s12905-020-01080-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530969/
https://www.ncbi.nlm.nih.gov/pubmed/33008401
http://dx.doi.org/10.1186/s12905-020-01080-9

Ejemplares similares